candycrush2022| Yonghe Medical (02279): spent HK$43,000 to repurchase 35,000 shares

Newsletter summary

Yonghe Medical (02279) cost 4.Candycrush2022HK $30,000 buyback 3Candycrush2022.50 million shares, the market pays attention to its financial performance and stock price dynamics.

candycrush2022| Yonghe Medical (02279): spent HK,000 to repurchase 35,000 shares

Text of news flash

[Yonghe Medical spent HK $43000 to buy back 35000 shares] Yonghe Medical (02279) revealed in its latest announcement that the company bought back through market transactions on May 8, 2024.Candycrush202235000 shares were sold, with a total transaction expense of HK $43000. The move aims to enhance shareholder value and enhance the company.Candycrush2022The market image of. Yonghe Medical stressed in the announcement that the company's management is dissatisfied with the current undervaluation of the stock price and believes that it does not fully reflect the true value of the company. The company conveys confidence in the future through buybacks and hopes to send a more positive message to investors. The announcement also mentioned that Yonghe Medical's buyback action is in line with relevant laws and regulations, and the company will closely monitor market developments to ensure compliance with the buyback process. Through this buyback, Yonghe Medical is expected to increase earnings per share, thereby increasing the wealth of shareholders. Yonghe Medical, as a leading enterprise in the medical field, this buyback behavior not only further strengthens its market position, but also shows confidence in future development and attention to investors. The company said that it will continue to pay attention to market changes and actively take measures to protect the interests of shareholders in order to achieve a win-win situation for both the company and shareholders. After the completion of this buyback, Yonghe Medical will continue to implement its long-term development strategy, expand market share, and take technological innovation and product optimization as the core to further enhance the company's market competitiveness. With the continuous deepening of the company in the medical field, investors can expect it to bring more surprises and value.

Powered By Z-BlogPHP 1.7.3